NanoViricides (NNVC) Starts Phase II Trial of NV-387 for Mpox in DRC

NanoViricides began patient enrollment in a Phase II (IIa/IIb), open-label, randomized trial of oral NV-387 for mpox in the Democratic Republic of Congo, evaluating efficacy and safety versus standard of care.Material DetailsContext by AI AnalystThis is an early-to-mid stage clinical milestone for…